About Molecular Sensing, Inc.
Molecular Sensing, Inc. (MSI), an early stage company located in the San Francisco Bay area, is dedicated to commercializing a new ,"game changing" molecular interaction biosensor technology, Back-Scattering Interferometry (BSI). BSI was invented by leading researchers at Vanderbilt University and addresses unmet needs in pharmaceutical drug discovery & development, biomedical research, and diagnostics. BSI overcomes the limitations of SPR and ITC, while combining their advantages in a single, synergistic platform.
We are currently partnering with biopharmaceutical companies and major academic centers through our
Life-science Early Access Program (LEAP) providing fee-based services that enable novel, high value drug discovery binding information beyond the capabilities of current technologies. Through LEAP, MSI and our partners are pioneering breakthroughs in drug discovery paradigms. LEAP also enables us to improve the performance, specifications and features of our first generation commercial instrument, guiding us in the production of a platform that will be well-suited to drug discovery applications. We anticipate placing the first release instrument systems in the labs of LEAP partners in 2010.
MSI is led by a strong team of life science industry veterans with more than 100 years combined experience in instrumentation, applications and business development. Our business model is geared toward rapid achievement of positive cash flow through our innovative LEAP services program creating market interest for rapid acceleration of instrument sales in the near future.